Literature DB >> 2537760

Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4.

H H Schmidt1, R Seifert, E Böhme.   

Abstract

Vascular endothelial cells and neutrophils synthesize and release potent vasodilatatory factors, i.e. endothelium-derived relaxing factors (EDRF) and neutrophil-derived relaxing factors (NDRF). One EDRF has been identified as nitric oxide (NO) derived from arginine. We studied the synthesis and release of NO from human neutrophils stimulated with the chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine, platelet activating factor or leukotriene B4. The formation and release of NO was enhanced several-fold in the presence of superoxide dismutase, probably by inhibiting superoxide-induced breakdown of NO. The formation and release of NO but not the formation of superoxide anions was decreased in neutrophils pretreated with L-canavanine, an inhibitor of arginine-utilizing enzymes. Our data suggest that at least one NDRF is identical with NO or another labile NO containing compound derived from arginine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537760     DOI: 10.1016/0014-5793(89)80562-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  49 in total

1.  The gills are an important site of iNOS expression in rainbow trout Oncorhynchus mykiss after challenge with the gram-positive pathogen Renibacterium salmoninarum.

Authors:  J J Campos-Perez; M Ward; P S Grabowski; A E Ellis; C J Secombes
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase.

Authors:  K Nishida; D G Harrison; J P Navas; A A Fisher; S P Dockery; M Uematsu; R M Nerem; R W Alexander; T J Murphy
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

3.  Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis.

Authors:  R D Curran; T R Billiar; D J Stuehr; J B Ochoa; B G Harbrecht; S G Flint; R L Simmons
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

4.  The cytosol of N1E-115 neuroblastoma cells synthesizes an EDRF-like substance that relaxes rabbit aorta.

Authors:  U Förstermann; K Ishii; L D Gorsky; F Murad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

5.  N-hydroxylamine is not an intermediate in the conversion of L-arginine to an activator of soluble guanylate cyclase in neuroblastoma N1E-115 cells.

Authors:  S Pou; W S Pou; G M Rosen; E E el-Fakahany
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

6.  Differential inhibition and potentiation of chemoattractant-induced superoxide formation in human neutrophils by the cell-permeant analogue of cyclic GMP, N2,2'-O-dibutyryl guanosine 3':5'-cyclic monophosphate.

Authors:  J Ervens; G Schultz; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

7.  Tissue injury caused by deposition of immune complexes is L-arginine dependent.

Authors:  M S Mulligan; J M Hevel; M A Marletta; P A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

8.  Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures.

Authors:  E Galea; D L Feinstein; D J Reis
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Nitric oxide-generating system as an autocrine mechanism in human polymorphonuclear leucocytes.

Authors:  A Riesco; C Caramelo; G Blum; M Montón; M J Gallego; S Casado; A López Farré
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

10.  Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy.

Authors:  J B Hibbs; C Westenfelder; R Taintor; Z Vavrin; C Kablitz; R L Baranowski; J H Ward; R L Menlove; M P McMurry; J P Kushner
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.